Disease Domain | Count |
---|---|
Neoplasms | 13 |
Endocrinology and Metabolic Disease | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Biological products | 5 |
CAR-M | 4 |
Antibody drug conjugate (ADC) | 3 |
Fusion protein | 1 |
Single-chain FV antibody fragment | 1 |
Target |
Mechanism EpCAM inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IL1R1 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IL-6 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Jan 2024 |
Sponsor / Collaborator |
Start Date16 Jun 2021 |
Sponsor / Collaborator |
Start Date02 Feb 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Oportuzumab monatox ( EpCAM ) | Non-Muscle Invasive Bladder Neoplasms More | Phase 3 |
EBI-031 ( IL-6 ) | Uveitis More | Phase 1 |
CT-0508 ( HER2 ) | Ovarian Epithelial Carcinoma More | Phase 1 |
CT-1119 ( MSLN ) | Solid tumor More | Preclinical |
VB-6011(Viventia Biotech, Inc.) | Neoplasms More | Preclinical |